Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma

作者：Bo Wu, Wenzhuo Yang, Zhaoyu Fu, Haoqun Xie, Zhen Guo, Daqun Liu, Junliang Ge, Sheng Zhong, Luwei Liu, Jingyi Liu, Dong Zhu · 发表于：Aging · 年份：2021 · DOI：10.18632/aging.203165 · 被引用次数：22 · 研究领域：Protein Degradation and Inhibitors、Computational Drug Discovery Methods、Advanced Breast Cancer Therapies

, MTT and colony formation assays demonstrated that PHA-793887 reduced the viability and clonogenicity of osteosarcoma cells, while a scratch assay suggested that PHA-793887 impaired the migration of these cells. Flow cytometry experiments revealed that PHA-793887 dose-dependently induced apoptosis in osteosarcoma cells. Western blotting and enzyme-linked immunosorbent assays indicated that CDK1 expression in osteosarcoma cells declined with increasing PHA-793887 concentrations. These results suggest that PHA-793887 could be a promising new treatment for osteosarcoma.